{"id":4417,"date":"2019-03-26T05:11:06","date_gmt":"2019-03-26T05:11:06","guid":{"rendered":"https:\/\/www.erdheim-chester.org\/?post_type=study_trials&#038;p=4417"},"modified":"2019-11-12T15:29:11","modified_gmt":"2019-11-12T15:29:11","slug":"eine-studie-zu-plx8394-als-monotherapie-bei-patienten-mit-fortgeschrittenen-inoperablen-soliden-tumoren","status":"publish","type":"study_trials","link":"https:\/\/www.erdheim-chester.org\/de\/study_trials\/a-study-of-plx8394-as-a-single-agent-in-patients-with-advanced-unresectable-solid-tumors\/","title":{"rendered":"Eine Studie zu PLX8394 als Monotherapie bei Patienten mit fortgeschrittenen, inoperablen soliden Tumoren"},"content":{"rendered":"<p><strong>Ziel der Studie:<\/strong>&nbsp; Das Ziel dieser klinischen Studie ist es, herauszufinden, wie sich PLX8394 auf Krebszellen mit Mutationen im BRAF-Gen auswirken k\u00f6nnte. PLX8394 wurde entwickelt, um Mutationen im BRAF-Gen zu blockieren. Diese Mutationen k\u00f6nnen Krebs verursachen und das Wachstum von Krebszellen f\u00f6rdern.\u00a0 Durch die Blockierung dieser Mutationen k\u00f6nnte das Medikament die Krebszellen mit der Mutation abt\u00f6ten und\/oder das Tumorwachstum stoppen.<\/p>\n<p><strong>Sponsor:<\/strong>&nbsp; Plexxikon<\/p>\n<p><strong>Kontaktdaten f\u00fcr die Testphase:<\/strong>&nbsp; Divya Sakamuri; 1-713-745-3296; dsakamuri@mdanderson.org oder Filip Janku; 713-563-1930; FJanku@mdanderson.org<\/p>\n<p><strong>Gew\u00fcnschte Einbeziehung des Patienten:<\/strong>&nbsp; ECD-Patienten, die \u00e4lter als 18 Jahre sind.<\/p>\n<p><strong>Bekannte Zentren, die ECD-Patienten in die Studie aufnehmen:<\/strong>&nbsp; MD Anderson, Houston, Texas<\/p>\n<p><strong>ClinicalTrials.gov-Kennung:<\/strong>&nbsp; NCT02428712<\/p>","protected":false},"excerpt":{"rendered":"<p>Study Objective:&nbsp; The goal of this clinical research study is to learn how PLX8394 may affect cancer cells with mutations in the gene BRAF.&nbsp; PLX8394 is designed to block mutations [&hellip;]<\/p>\n","protected":false},"featured_media":0,"parent":0,"menu_order":0,"template":"","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","cybocfi_hide_featured_image":"","wds_primary_study_trials_cat":0,"_links_to":"","_links_to_target":""},"study_trials_cat":[32],"class_list":["post-4417","study_trials","type-study_trials","status-publish","hentry","study_trials_cat-drug-trial"],"_links":{"self":[{"href":"https:\/\/www.erdheim-chester.org\/de\/wp-json\/wp\/v2\/study_trials\/4417","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erdheim-chester.org\/de\/wp-json\/wp\/v2\/study_trials"}],"about":[{"href":"https:\/\/www.erdheim-chester.org\/de\/wp-json\/wp\/v2\/types\/study_trials"}],"wp:attachment":[{"href":"https:\/\/www.erdheim-chester.org\/de\/wp-json\/wp\/v2\/media?parent=4417"}],"wp:term":[{"taxonomy":"study_trials_cat","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/de\/wp-json\/wp\/v2\/study_trials_cat?post=4417"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}